Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2003 Nov;9(11):2583-6.
doi: 10.3748/wjg.v9.i11.2583.

Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude

Affiliations
Clinical Trial

Effect of a single oral dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude

Jin-Yan Luo et al. World J Gastroenterol. 2003 Nov.

Abstract

Aim: To study the effect of rabeprazole (RAB) on nocturnal acid breakthrough (NAB) and nocturnal alkaline amplitude (NAKA) and to compare it with omeprazole (OME) and pantoprazole (PAN).

Methods: By an open comparative study, forty patients with active peptic ulcer were randomly assigned to receive one of the three PPIs (proton pump inhibitor) with a single oral dose. They were divided into RAB group (10 mg), OME group (20 mg) and PAN group (40 mg). Twenty healthy volunteers were enrolled to the control group (without taking any drug). Intragastric pH monitoring was then performed 1 hour before and 24 hours after the dose was given.

Results: No clinically undesirable signs and symptoms possibly attributed to the administration of RAB or OME and PAN were recognizable throughout the study period. All subjects completed the study according to the protocol. All data were processed by a computer using the Student t test or t' test followed by an analysis of covariance. P<0.05 was considered to have statistical significance. The intragastric pH of NAB was significantly higher in RAB group (1.84+/-0.55) than in either OME group (1.15+/-0.31) or PAN group (1.10+/-0.30) (both P<0.01). RAB produced a longer sustaining time (4.65+/-1.22 h) on NAKA than OME (3.22+/-1.89 h) (P<0.05), PAN (3.15+/-1.92 h) (P<0.05), and the sustaining time of NAKA in RAB group was longer than that in the healthy control group (P<0.01) too. In addition, RAB produced a much higher pH on NAKA (6.41+/-0.45) in comparison with PAN (6.01+/-0.92) (P<0.05).

Conclusion: A single oral dose of 10 mg RAB may increase the pH of NAB and shorten the sustaining time of NAB, and it may increase the pH of NAKA as well as prolong the sustaining time of NAKA.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Simulating figure of NAB and NAKA. NAB and NAKA all occurred after midnight, and NAKA always appeared after NAB. Compared with the control group (didn’t receive either PPI or placebo), RAB increased the pH of NAKA as well as prolonged the persisting time of NAKA.

Similar articles

Cited by

References

    1. Tytgat GN. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatol. 2001;13 Suppl 1:S29–S33. - PubMed
    1. Sachs G. Improving on PPI-based therapy of GORD. Eur J Gastroenterol Hepatol. 2001;13 Suppl 1:S35–S41. - PubMed
    1. Gong J, Zhu YL, Luo JY, Wang XQ. The acid-inhibiting effect of famotidine with a single dose by injection in musle. Zhonghua Yixue Zazhi. 1998;37:762–765.
    1. Peghini PL, Katz PO, Bracy NA, Castell DO. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol. 1998;93:763–767. - PubMed
    1. Bianco A, Cagossi M, Piraccini R, Castrucci G, Greco AV. The nightly spontaneous alkalinization of the stomach. Riv Eur Sci Med Farmacol. 1993;15:17–27. - PubMed